Knockdown of TRAF4 expression suppresses osteosarcoma cell growth in vitro and in vivo

Yao,Weitao; Wang,Xin; Cai,Qiqing; Gao,Songtao; Wang,Jiaqiang; Zhang,Peng

doi:10.3892/ijmm.2014.1948

Knockdown of TRAF4 expression suppresses osteosarcoma cell growth in vitro and in vivo

Authors:
- Weitao Yao
- Xin Wang
- Qiqing Cai
- Songtao Gao
- Jiaqiang Wang
- Peng Zhang
View Affiliations

Affiliations: Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 45000, P.R. China
Published online on: September 29, 2014 https://doi.org/10.3892/ijmm.2014.1948
Pages: 1655-1660

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor (TNF) receptor‑associated factor 4 (TRAF4) is an adapter molecule that is overexpressed in certain cancers. TRAF4 is overexpressed in osteosarcoma tissues and osteosarcoma cells. Using the technique of RNA interference, the expression of TRAF4 in the human osteosarcoma Saos‑2 cell line was shown to be downregulated. The proliferation, cell cycle arrest and apoptosis ability of Saos‑2 cells were examined, as was tumor development in a xenograft mouse model. The results showed that the TRAF4 knockdown exerts inhibitory effects on the proliferation ability of Saos‑2 cells and tumor development in a xenograft mouse model. Simultaneously, it was found that TRAF4 knockdown led to cell cycle arrest in the G1 phase and promoted Saos‑2 cell apoptosis. Following TNF‑α treatment, the expression of nuclear factor κB was significantly reduced in the TRAF4‑small interfering RNA group. These results indicate that TRAF4 regulated osteosarcoma cell growth in vitro and in vivo, and offers a candidate molecular target for osteosarcoma prevention and therapy.

View Figures

View References

1	Zhao H, Li M, Li L, Yang X, Lan G and Zhang Y: MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
2	Shimbo K, Miyaki S, Ishitobi H, Kato Y, Kubo T, Shimose S and Ochi M: Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem Biophys Res Commun. 445:381–387. 2014. View Article : Google Scholar : PubMed/NCBI
3	Pierz KA, Womer RB and Dormans JP: Pediatric bone tumors: osteosarcoma ewing’s sarcoma, and chondrosarcoma associated with multiple hereditary osteochondromatosis. J Pediatr Orthop. 21:412–418. 2001.
4	Yang C, Hou C, Zhang H, Wang D, Ma Y, Zhang Y, Xu X, Bi Z and Geng S: miR-126 functions as a tumor suppressor in osteosarcoma by targeting Sox2. Int J Mol Sci. 15:423–437. 2014. View Article : Google Scholar : PubMed/NCBI
5	Xie ZG, Xie Y and Dong QR: Inhibition of the mammalian target of rapamycin leads to autophagy activation and cell death of MG63 osteosarcoma cells. Oncol Lett. 6:1465–1469. 2013.PubMed/NCBI
6	Xie P: TRAF molecules in cell signaling and in human diseases. J Mol Signal. 8:72013. View Article : Google Scholar : PubMed/NCBI
7	Wajant H, Henkler F and Scheurich P: The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal. 13:389–400. 2001. View Article : Google Scholar : PubMed/NCBI
8	Ha H, Han D and Choi Y: TRAF-mediated TNFR-family signaling. Curr Protoc Immunol. Chapter 11(Unit 11.9D)2009.PubMed/NCBI
9	Arron JR, Walsh MC and Choi Y: TRAF-mediated TNFR-family signaling. Curr Protoc Immunol. Chapter 11(Unit 11.9D)2002.PubMed/NCBI
10	Tomasetto C, Regnier CH and Rio MC: TRAF-4 expression in breast carcinomas. Am J Pathol. 153:2007–2008. 1998. View Article : Google Scholar : PubMed/NCBI
11	Camilleri-Broët S, Cremer I, Marmey B, Comperat E, Viguié F, Audouin J, Rio MC, Fridman WH, Sautès-Fridman C and Régnier CH: TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene. 26:142–147. 2007.PubMed/NCBI
12	Marinis JM, Homer CR, McDonald C and Abbott DW: A novel motif in the Crohn’s disease susceptibility protein, NOD2, allows TRAF4 to down-regulate innate immune responses. J Biol Chem. 286:1938–1950. 2011.PubMed/NCBI
13	Qin GQ, He HC, Han ZD, Liang YX, Yang SB, Huang YQ, Zhou L, Fu H, Li JX, Jiang FN and Zhong WD: Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer. Onco Targets Ther. 7:137–146. 2014.PubMed/NCBI
14	Tayarani-Najaran Z, Asili J, Aioubi E and Emami SA: Growth inhibition and apoptosis induction of Salvia chloroleuca on MCF-7 breast cancer cell line. Iran J Pharm Res. 12:789–799. 2013.
15	Zhang B, Lu Z, Hou Y, Hu J and Wang C: The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells. Tumour Biol. 35:5401–5407. 2014. View Article : Google Scholar : PubMed/NCBI
16	Meng Q, Zheng M, Liu H, Song C, Zhang W, Yan J, Qin L and Liu X: TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol Cell Biochem. 371:177–186. 2012. View Article : Google Scholar : PubMed/NCBI
17	Li X, Huang T, Jiang G, Gong W, Qian H and Zou C: Synergistic apoptotic effect of crocin and cisplatin on osteosarcoma cells via caspase induced apoptosis. Toxicol Lett. 221:197–204. 2013. View Article : Google Scholar : PubMed/NCBI
18	Guo F, Sun A, Wang W, He J, Hou J, Zhou P and Chen Z: TRAF1 is involved in the classical NF-κB activation and CD30-induced alternative activity in Hodgkin’s lymphoma cells. Mol Immunol. 46:2441–2448. 2009.
19	Zheng H, Liu C, Ou Y, Zhang Y and Fu X: Total saponins of Panax notoginseng enhance VEGF and relative receptors signals and promote angiogenesis derived from rat bone marrow mesenchymal stem cells. J Ethnopharmacol. 147:595–602. 2013.
20	Yang WT and Zheng PS: Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis. PLoS One. 9:e888272014. View Article : Google Scholar : PubMed/NCBI
21	Garrington GE, Scofield HH, Cornyn J and Hooker SP: Osteosarcoma of the jaws. Analysis of 56 cases. Cancer. 20:377–391. 1967. View Article : Google Scholar : PubMed/NCBI
22	Geller DS and Gorlick R: Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
23	Tomasetto C, Régnier C, Moog-Lutz C, Mattei MG, Chenard MP, Lidereau R, Basset P and Rio MC: Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics. 28:367–376. 1995. View Article : Google Scholar : PubMed/NCBI
24	Fleckenstein DS, Dirks WG, Drexler HG and Quentmeier H: Tumor necrosis factor receptor-associated factor (TRAF) 4 is a new binding partner for the p70S6 serine/threonine kinase. Leuk Res. 27:687–694. 2003. View Article : Google Scholar : PubMed/NCBI
25	Sax JK and El-Deiry WS: Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem. 278:36435–36444. 2003. View Article : Google Scholar : PubMed/NCBI
26	Esparza EM and Arch RH: TRAF4 functions as an intermediate of GITR-induced NF-κB activation. Cell Mol Life Sci. 61:3087–3092. 2004.PubMed/NCBI
27	Beg AA and Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274:782–784. 1996. View Article : Google Scholar : PubMed/NCBI